Severe Asthma

NASHVILLE, Tenn. — Experts found both consensus and contention during a roundtable discussion of the use of biologics to treat severe asthma, modelled on the ESPN program “Pardon the Interruption,” during the CHEST Annual Meeting.

NASHVILLE, Tenn. — Patients with asthma who experience anaphylaxis have higher rates of complications, 30-day readmissions and mortality than those without anaphylaxis, according to a presentation at the CHEST Annual Meeting.

The addition of breathing exercises to usual care enhanced asthma-related quality of life in patients with incompletely controlled asthma, regardless of severity, without evidence of causing harm, according to study results.

Patients with severe asthma who are on subcutaneous immunotherapy for allergy treatment do not experience an increased risk for moderate to severe systemic reactions, according to a study published in Annals of Allergy, Asthma & Immunology.

Patients who received biologic treatment for asthma did not experience higher SARS-CoV-2 infection rates than the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Mepolizumab reduced the need for maintenance oral corticosteroids and systemic corticosteroid bursts among patients with severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Dupilumab treatment reduced asthma exacerbations among patients both with and without evidence of fungal sensitization on medium- or high-dose inhaled corticosteroids, according to a post hoc analysis of the LIBERTY ASTHMA QUEST study.

Patients who began taking or who switched biologics for severe asthma consistently experienced meaningfully reduced exacerbations, according to a real-world analysis published in Annals of Allergy, Asthma & Immunology.

Severe exacerbations that occur early in the course of asthma impacted the course of the disease and risk for subsequent exacerbations in children and adults, researchers reported in the Annals of the American Thoracic Society.

SAN FRANCISCO — In this video exclusive, Njira L. Lugogo, MD, details a new analysis of the NAVIGATOR study in which more patients with severe, uncontrolled asthma treated with tezepelumab achieved on-treatment clinical response vs. placebo.